chemestmed.comCrawled Oct 24, 2026
L. Ivanova, K. Naumenko, M. Varjak, S. Koit, Y. Morozovsky, A. Merits, M. Karelson, E. Zusinaite. Dengue Virus Inhibitors as Potential Broad-Spectrum Flavivirus Inhibitors. Pharmaceuticals. 2025; 18(3):283. https://doi.org/10.3390/ph18030283.
Riia tn 130b/2 Tartu, Tartumaa 50411 Estonia
Epitranscriptomics research explores RNA chemical modifications and their roles in cells, offering potential treatments for previously undruggable disease pathways.
Epitranscriptomics research explores RNA chemical modifications and their roles in cells, offering potential treatments for previously undruggable disease pathways.
Chemestmed is developing RNA-based drug candidates targeting severe diseases through a novel mechanism of action. The company focuses on influencing disease progression to potentially improve patient outcomes. This approach leverages advanced biotechnology to address unmet medical needs.
Oct 2026Global Health ConnectorNews article
Chemestmed is developing RNA-based drug candidates that target disease progression by restoring and regulating RNA methylation balance. The company leverages a novel mechanism to potentially address severe illnesses. Based in Estonia, Chemestmed operates within the Tehnopol HealthTech ecosystem.
Jul 2026TehnopolNews article
CALM6A develops a novel bi-functional activator targeting the METTL3-14 complex to restore m6A RNA balance, addressing the unmet need for disease-modifying treatments in generalized anxiety disorder (GAD). Current therapies for GAD, which affects over 5% of Europeans, often fail to provide lasting relief or are poorly tolerated. The project aims to intervene at the molecular level of stress dysregulation, a pathway not targeted by existing approved treatments.
Jun 2026CORDIS | European CommissionNews article
